Solid Biosciences Inc.
http://solidbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Solid Biosciences Inc.
Finance Watch: Kyverna, Alto Offerings Could Land In IPO Investors’ Sweet Spot
Public Company Edition: Kyverna and Alto Neuroscience, which may go public in the US this year, have drug candidates in or nearing mid-stage trials. Also, Zealand’s private placement raises $211.4m, Praxis prices a $150m offering and Solid grosses $108.9m in stock sale.
Biogen Buys Time For Leqembi Ramp-Up With Reata Acquisition
By agreeing to pay $7.3bn for Reata and its Friedrich’s ataxia drug Skyclarys, “recalibrating” Biogen can be more patient with launches of Alzheimer’s drug Leqembi and ALS therapy Qalsody.
In Seeking ‘Strategic Alternatives’ Avrobio Is Confronting Gene Therapy Reality
Avrobio is facing up to the reality of investor skepticism about gene therapy platforms and business models – but can it find a buyer or merger partner to start again?
Biopharma Investors, Companies Learning To Adjust To Financial Market Realities
Raising money will be difficult for the foreseeable future, so every part of the ecosystem from start-ups to public companies to VC firms is figuring out how to survive until cash is easily accessible again.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- AavantiBio Inc.
- Solid GT
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice